在阿尔茨海默病中的新型基因组后翻译性修饰:目前的进展和影响
Yuanyuan Qin1,2,3,4, Ping Yang1,2,3,4, Wanhong He1,2,3,4
1Department of Nephrology, The Affiliated Hospital of Southwest Medical University, 25 Taiping Rd, Jiangyang District, Luzhou, 646000, Sichuan, People's Republic of China.
Clinical epigenetics
|March 9, 2024
概括
新型基因组转化后修饰 (HPTMs) 越来越多地与阿尔茨海默氏病 (AD) 发病有关. 本综述探讨了这些新的HPTM,它们的代谢联系,以及对AD的潜在治疗影响.
科学领域:
- 神经科学是一个神经科学.
- 生物化学 生物化学
- 遗传学 是一个遗传学.
背景情况:
- 阿尔茨海默病 (AD) 的发病过程很复杂,基因组转化后修饰 (HPTM) 起着关键作用.
- 基斯乙化是一种成熟的HPTM,与AD有关.
- 新兴研究突出显示了AD中的新型HPTM.
研究的目的:
- 审查与阿尔茨海默病相关的新型HPTM的当前进展.
- 探索这些新型HPTM在AD病变发生过程中的影响.
- 为开发AD的新型治疗策略提供见解.
主要方法:
- 关于新型HPTM和AD的最近研究的文献综述.
- 分析质谱和蛋白质组学数据,识别新型HPTM.
- 综合链接物质代谢,基因调节和AD的信息.
主要成果:
- 新型HPTM的鉴定,包括乳酸化,克罗化,β-基化,2-基化,化和化.
- 这些新型HPTM在物质代谢和基因调节之间建立了联系.
- 越来越多的证据将这些新型HPTM与阿尔茨海默病联系起来.
结论:
- 新型HPTM提供了对阿尔茨海默氏症复杂病原学的更深入的了解.
- 了解这些修改可能会导致开发新的治疗点和AD的药物.
- 对新型HPTM的进一步研究对于推进AD治疗至关重要.
相关概念视频
Alzheimer's Disease: Overview
481
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
481
Alzheimer's Disease: Treatment
188
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
188
Spreading of Chromatin Modifications
8.3K
The histone proteins in the nucleosomes are post-translationally modified (PTM) to increase or decrease access to DNA. The commonly observed PTMs are methylation, acetylation, phosphorylation, and ubiquitination of lysine amino acids in the histone H3 tail region. These histone modifications have specific meaning for the cell. Hence, they are called "histone code". The protein complex involved in histone modification is termed as "reader-writer" complex.
Writers
The writer...
Writers
The writer...
8.3K
Histone Modification
3.4K
3.4K
Histone Variants at the Centromere
4.3K
Histone variants are the histone proteins with structural and sequence variations. These variants may be regarded as “mutant” forms that replace their canonical histone counterparts in the nucleosomes. Specific post-translational modifications on the histone variants enable further chromatin complexity and regulate tissue-specific gene expression. The most common histone variants are from histone H2A, H2B, and linker histone H1 families. However, several variants of histone H3...
4.3K
Amyloid Fibrils
9.5K
Amyloid fibrils are aggregates of misfolded proteins. Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils.
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
9.5K


